AIQ's medical device technology platform provides a better understanding of treatment response, helping clinicians more effectively treat complex diseases.
AIQ Solutions was built with the clinical care team in mind. Our technology makes it easy for reports to be worked on together so the whole care team has insight and understanding of the patients’ treatment response to therapy. AIQ ensures that each member of the care team has access to the patient's Treatment Response Assessment report and can use the information to evaluate and optimize their patient’s treatment.
Every day, you are challenged with trying to understand how disease evolves within your patient while at the same time, under pressure to reduce treatment costs. Our technology platform supplies intelligence, analytics, and insights you cannot get from other medical devices. We help you make a real difference for your patients, every day. Our technology provides the information to help understand the tough battles and strategies for treatment management options.
For complex diseases, intra-patient response is heterogeneous
Heterogeneous treatment response impacts clinical outcomes. AIQ's Treatment Response Assessment Report provides the intelligence to help understand these responses.
AIQ's medical device technology platform will help you understand your patient’s response to treatment sooner and more comprehensively, enabling real-time changes in management of care
By using algorithmic analysis for detecting the volume of lesions, determining their boundaries, quantifying disease burden, and assessing temporal change, AIQ’s technology provides accurate evaluations of treatment response. You get both graphical and quantitative data faster, allowing you to focus on interpreting the patient’s condition and recommending changes to the care plan. What we offer does not replace your medical expertise; it amplifies it. AIQ broadens the information landscape available to treat patients, using information that is reliable, proven, and actionable.
Your impact on the patient’s care plan depends on the data you receive. Having more informative biomarkers of treatment response in real time, will help you make more valuable patient management recommendations.
AIQ’s medical device technology platform is efficient, allowing you to focus on the clinical interpretation that leads to better patient care.
AIQ’s technology does not replace your medical expertise. Our technology only enhances your medical knowledge, not replace it.
Prostate cancer metastatic to bone
Nonsteroidal antiandrogen medication
Clinical indicators, including PSA, stable for 12 months following treatment; however, at week 54 PSA began to climb and patient reported new pain in pelvis
Single lesion on pelvis has increased in size
Given new pain with increase in PSA levels, a decision was made to switch therapy to a chemotherapy medication
Significant clinical progression within 8 weeks
This patient’s treatment response was evaluated by AIQ retroactively at 12, 54, and 62 weeks into treatment. At 12 weeks there was a substantial decrease in tumor burden with majority of lesions improving on therapy.
Repeat evaluation by AIQ at week 54 shows progressive disease in the left pelvis with remainder of disease stable to improved.
A subsequent evaluation at 8 weeks after switching to chemotherapy medication shows not only ongoing progression in the left pelvis, but also disease progression among many of the lesions which were still responding to the nonsteroidal antiandrogen medication at 54 weeks.
Had AIQ's medical device technology platform been available, a decision to change the patient's care pathway and administer localized radiation to the left pelvis could have been made allowing the patient to maintain disease control on his nonsteroidal antiandrogen therapy. Because most lesions were still responding well to that therapy, this approach may have prevented the negative outcomes subsequently observed.